Blog

Continue Reading

  • Max Verstappen pleased with P2 in ‘super difficult’ conditions during Las Vegas Qualifying

    Max Verstappen pleased with P2 in ‘super difficult’ conditions during Las Vegas Qualifying

    Max Verstappen hailed his P2 result in Qualifying at the Las Vegas Grand Prix as “good for us”, with the Red Bull driver pleased to manage the “super difficult” conditions en route to a front row start.

    Amid varied weather throughout the…

    Continue Reading

  • The burden of diabetes nephropathy in China from 1990 to 2021, with forecast to 2036.: an analysis from the global burden of disease study 2021 | BMC Public Health

    The burden of diabetes nephropathy in China from 1990 to 2021, with forecast to 2036.: an analysis from the global burden of disease study 2021 | BMC Public Health

  • Samsu N. Diabetic nephropathy: challenges in Pathogenesis, Diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449.

    Google Scholar 

  • Peride I, Anastasiu M, Serban SA et al. The key role of nutritional…

    • Continue Reading

  • Top cardiologist reveals the one morning habit that causes the maximum number of heart attacks within the first 10 minutes of waking up (not food or stress!)

    Top cardiologist reveals the one morning habit that causes the maximum number of heart attacks within the first 10 minutes of waking up (not food or stress!)

    Most heart attacks happen in the early morning hours, between 6 and 10 a.m., and the reasons go beyond traditional risk factors like cholesterol or age. Dr. Heigl, a senior cardiologist at Vienna General Hospital, who studied over 12,000…

    Continue Reading

  • No. 19 UCLA Rolls Past Presbyterian, 86-46

    No. 19 UCLA Rolls Past Presbyterian, 86-46

    LOS ANGELES – The No. 19-ranked UCLA men’s basketball team delivered an electrifying offensive performance in an 86-46 nonconference victory over Presbyterian on Friday evening inside Pauley Pavilion presented by Wescom Financial.
     
    UCLA…

    Continue Reading

  • Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025?

    Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025?

    • Wondering if Pfizer is a smart buy at today’s price? You are not alone, especially as value-focused investors begin to focus on the stock.

    • Pfizer’s performance has been mixed lately. Shares dipped just 0.1% in the last week, inched up 1.3% over the past month, but are still down 5.9% year to date despite a 4.7% return over the last twelve months.

    • Recent headlines about Pfizer have focused on its latest product developments and major moves in the pharmaceutical sector, generating speculation about the company’s future direction. These stories give investors plenty to consider regarding long-term growth prospects and short-term uncertainty.

    • In terms of valuation, Pfizer scores a strong 5 out of 6 on our core checklist for undervaluation, making it a notable candidate for deeper analysis. Next, let us explore the valuation methods that matter, and stay tuned for a perspective that goes beyond the numbers alone.

    Find out why Pfizer’s 4.7% return over the last year is lagging behind its peers.

    A Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and discounting them back to their value today. This helps investors see what those future dollars are worth in today’s terms.

    For Pfizer, the latest reported Free Cash Flow (FCF) stands at $9.95 Billion. Analysts forecast that FCF will grow steadily, with Simply Wall St extrapolating a projected FCF of $16.36 Billion in the year 2029. While analyst estimates usually cover the next five years, these longer-term numbers are model driven based on known cash flow trends.

    Based on these projections and the DCF methodology, the estimated intrinsic value of Pfizer’s shares comes out to $62.40. This is a striking 59.9% higher than the current market price, indicating that the stock trades at a substantial discount according to this valuation.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 59.9%. Track this in your watchlist or portfolio, or discover 917 more undervalued stocks based on cash flows.

    PFE Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pfizer.

    For companies like Pfizer that consistently generate profits, the Price-to-Earnings (PE) ratio is a popular and reliable valuation tool. The PE ratio tells investors how much they are paying for each dollar of current earnings, providing a useful snapshot for comparing across companies and industries.

    It is important to remember that what counts as a “normal” or “fair” PE ratio varies depending on a company’s growth expectations and risk profile. Companies with higher expected earnings growth or lower risk typically justify a higher PE, while those with slower growth or greater risk generally trade on a lower multiple.

    At the moment, Pfizer trades on a PE ratio of 14.53x. This is noticeably below both the industry average of 19.92x and the peer group average of 17.05x. However, benchmarks like industry averages do not always tell the whole story.

    That is where the Simply Wall St Fair Ratio comes in. The Fair Ratio for Pfizer is calculated at 24.17x, reflecting a more personalized estimate based on Pfizer’s growth prospects, profit margin, industry environment, company size, and business risks. This proprietary metric offers a more tailored and holistic view of what could be considered a reasonable valuation for Pfizer compared to industry and peer averages that may not fully capture company-specific factors.

    Given that Pfizer’s current PE of 14.53x is well below its Fair Ratio of 24.17x, the evidence suggests Pfizer is undervalued on this preferred metric.

    Result: UNDERVALUED

    NYSE:PFE PE Ratio as at Nov 2025
    NYSE:PFE PE Ratio as at Nov 2025

    PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1422 companies where insiders are betting big on explosive growth.

    Earlier we mentioned there is an even better way to understand valuation, so let us introduce you to Narratives. In investing, a Narrative is your perspective on a company’s future, connecting the story you believe about its business, such as growth in new markets, product launches, or risk factors, to your own estimates for revenue, earnings, and margins.

    Narratives make investing smarter and more personalized by linking your view of Pfizer’s story directly to a dynamic financial forecast and fair value estimate. This approach is easy to use and available to all on Simply Wall St’s Community page, where millions of investors share their views and track company progress.

    With Narratives, you can see how your fair value estimate compares to today’s market price. This makes it easier to decide when a stock might be a buying opportunity or when it may be time to take profits. Even better, as new data or news emerges, each Narrative updates automatically, keeping your analysis current without any extra effort.

    For Pfizer, some investors see fair value as high as $35.77 per share (expecting margin expansion and accelerated innovation), while others estimate as low as $24.00 (citing patent risks and margin pressure).

    For Pfizer, we’ll make it really easy for you with previews of two leading Pfizer Narratives:

    🐂 Pfizer Bull Case

    Fair Value: $29.08

    Undervalued by 13.9%

    Expected Revenue Growth Rate: -2.66%

    • Growth strategy focuses on expansion in innovative therapies and global emerging markets. The goal is to achieve margin improvement and resilience despite industry pressures.

    • Recent deals and digital investments, such as the Metsera acquisition and AI-powered R&D, are expected to drive long-term earnings growth and operational efficiencies.

    • Risks include regulatory pressures, patent expirations, and fierce competition. Consensus analyst targets indicate upside of 14.4% from current pricing.

    🐻 Pfizer Bear Case

    Fair Value: $24.00

    Overvalued by 4.3%

    Expected Revenue Growth Rate: -4.21%

    • Stricter drug price controls, ongoing patent expirations, and intensifying generic competition are expected to pressure Pfizer’s revenues and margins over the next several years.

    • Heavy reliance on bringing new R&D assets to market introduces risk, as pipeline delays or failures may not offset losses from established drugs.

    • Bears believe the company is fairly to slightly overvalued at its current price. This makes downside risks more prominent than potential upside under these assumptions.

    Do you think there’s more to the story for Pfizer? Head over to our Community to see what others are saying!

    NYSE:PFE Community Fair Values as at Nov 2025
    NYSE:PFE Community Fair Values as at Nov 2025

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include PFE.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Thunder score 22 straight points in huge 3rd quarter to rout Jazz

    Thunder score 22 straight points in huge 3rd quarter to rout Jazz

    Nov 22, 2025, 01:22 AM ET

    SALT LAKE CITY — Shai Gilgeous-Alexander scored 31 points, Oklahoma City had a 33-4 run and the defending champion Thunder routed the Utah Jazz 144-112 on Friday night in NBA Cup play to improve to 16-1 and push their…

    Continue Reading

  • Assessing Merit Medical Systems After Recent Portfolio Expansion and Share Price Rebound

    Assessing Merit Medical Systems After Recent Portfolio Expansion and Share Price Rebound

    • Wondering if Merit Medical Systems is trading at a bargain or if that ship has sailed? You are not alone; it is a common question for investors sizing up this healthcare stock.

    • The stock has seen a gentle rebound lately, up 2.5% over the last week and 3.2% this month, though longer-term returns remain muted with a -17.2% drop over the last year.

    • Recent headlines highlight increased interest in the company’s expanding medical device portfolio, as well as continued partnerships in the U.S. and abroad. These developments have offered a glimmer of optimism amid a period of share price volatility.

    • On a pure numbers basis, Merit Medical Systems currently scores 0 out of 6 on our core valuation checks, suggesting it may not be undervalued by traditional metrics. Stick around, as we will break down exactly how these checks work and reveal a smarter way to evaluate value later in the article.

    Merit Medical Systems scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Discounted Cash Flow (DCF) model estimates a company’s worth by forecasting future cash flows and discounting them back to today’s value to reflect risk and the time value of money. DCF is one of the most widely used valuation tools for fundamental investors.

    For Merit Medical Systems, the DCF calculation starts with the company’s current Free Cash Flow, which is $213 million. Based on analyst forecasts, Free Cash Flow is projected to grow steadily, reaching $229 million by the end of 2027. Beyond that, future projections are extrapolated, with cash flows expected to rise gradually each year and reach roughly $295 million in 2035.

    The DCF analysis uses these cash flow projections to arrive at an intrinsic value per share of $77.71. When compared to the current share price, the result suggests the stock is trading about 12.2% above its DCF-assessed fair value. This implies it may be overvalued at recent prices.

    Result: OVERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems may be overvalued by 12.2%. Discover 917 undervalued stocks or create your own screener to find better value opportunities.

    MMSI Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Merit Medical Systems.

    The price-to-earnings (PE) ratio is a popular valuation metric, especially for profitable companies like Merit Medical Systems. It reflects the amount investors are willing to pay today for each dollar of the company’s earnings. Generally, a higher PE suggests expectations of stronger future growth, while a lower PE may mean slower growth or higher perceived risk.

    Continue Reading

  • No. 1 Purdue tops No. 15 Tech at Baha Mar Championship

    No. 1 Purdue tops No. 15 Tech at Baha Mar Championship

    NASSAU, Bahamas – No. 1 Purdue turned a close game early into a Baha Mar Championship Final blowout with a 23-3 run to end the first half and never let up in an 86-56 win over No. 15 Texas Tech on Friday at the Baha Mar Convention, Arts and…

    Continue Reading

  • No. 3 Denver Wins 7-1 at Arizona State

    No. 3 Denver Wins 7-1 at Arizona State

    Continue Reading